Co-Diagnostics, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
CODX$0.32+24.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $2,936,544 | $14,916,878 |
| Marketable investment securities | 26,811,098 | 43,631,510 |
| Accounts receivable, net | 132,570 | 303,926 |
| Inventory, net | 1,072,724 | 1,664,725 |
| Income taxes receivable | - | 26,955 |
| Prepaid expenses and other current assets | 1,338,762 | 1,597,114 |
| Total current assets | 32,291,698 | 62,141,108 |
| Property and equipment, net | 2,761,280 | 3,035,729 |
| Operating lease right-of-use asset | 2,114,876 | 2,966,774 |
| Intangible assets, net | 26,101,000 | 26,403,667 |
| Investment in joint venture | 731,065 | 773,382 |
| Total assets | $63,999,919 | $95,320,660 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $3,294,254 | $1,482,109 |
| Accrued expenses | 2,562,169 | 2,172,959 |
| Operating lease liability, current | 915,619 | 838,387 |
| Contingent consideration liabilities, current | 502,819 | 891,666 |
| Deferred revenue | 40,857 | 362,449 |
| Total current liabilities | 7,315,718 | 5,747,570 |
| Long-term liabilities | ||
| Income taxes payable | 713,643 | 659,186 |
| Operating lease liability | 1,236,560 | 2,152,180 |
| Contingent consideration liabilities | 422,080 | 748,109 |
| Total long-term liabilities | 2,372,283 | 3,559,475 |
| Total liabilities | 9,688,001 | 9,307,045 |
| Commitments and contingencies (Note 12) | - | - |
| Stockholders’ equity | ||
| Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | - | - |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 37,902,222 shares issued and 33,053,544 shares outstanding as of December 31, 2024 and 36,108,346 shares issued and 31,259,668 shares outstanding as of December 31, 2023 | 37,902 | 36,108 |
| Treasury stock, at cost; 4,848,678 shares held as of December 31, 2024 and December 31, 2023, respectively | (15,575,795) | (15,575,795) |
| Additional paid-in capital | 102,472,210 | 96,808,436 |
| Accumulated other comprehensive income | 418,443 | 146,700 |
| Accumulated earnings (deficit) | (33,040,842) | 4,598,166 |
| Total stockholders’ equity | 54,311,918 | 86,013,615 |
| Total liabilities and stockholders’ equity | $63,999,919 | $95,320,660 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.